Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma
β Scribed by Kristine A. Donovan; Brent J. Small; Michael A. Andrykowski; Frederick A. Schmitt; Pamela Munster; Paul B. Jacobsen
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 98 KB
- Volume
- 104
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND The longβterm impact of breast carcinoma and its treatment was assessed in 153 breast carcinoma survivors previously treated on a Phase III randomized trial (Cancer and Leukemia Group B [CALGB 7581]) a median of 20 years after entry to CALGB 7581. ## METHODS Survivors w
## Abstract ## BACKGROUND In the U.S., the majority of premenopausal patients with earlyβstage breast carcinoma are treated with adjuvant chemotherapy. However, to the authors' knowledge, there have been few formal analyses of adjuvant chemotherapy cost performed to date, especially in premenopaus